Biostar Pharmaceuticals, Inc. to Host Fiscal 2010 Fourth Quarter and Year End Earnings Conference Call on Friday, March 25, 2011 at 10:00 a.m. ET
XIANYANG, China, March 22, 2011 /PRNewswire-Asia-FirstCall/ — Biostar Pharmaceuticals, Inc. (Nasdaq: BSPM) (“Biostar” or “the Company”), Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, XinAoxingOleanolic Acid Capsules (“XinAoxing Capsules”), today announced that its 2010 fourth quarter and year-end financial results will be released before the market open on Friday, March 25, 2011. A conference call to discuss the results is scheduled at 10:00 a.m. ET, Friday, March 25, 2011.
Interested parties may access the call by dialing + 1-877-941-4775 from within the United States, or +1-480-629-9761 if calling internationally. The conference ID is 4427253. It is advisable to dial in approximately 5-10 minutes prior to the start of the call.
A playback will be available through April 1, 2011. To listen, please call +1-877-870-5176 within the United States or +1-858-384-5517 when calling internationally. Utilize the pass code 4427253 for the replay.
This call is being web cast by ViaVid Broadcasting and can be accessed at ViaVid’s website at http://www.viavid.net or at the following link: http://viavid.net/dce.aspx?sid=0000835A .
About Biostar Pharmaceuticals, Inc.
Biostar Pharmaceuticals, Inc., through its wholly-owned subsidiary and controlled affiliate in China, develops, manufactures and markets pharmaceutical and health supplement products for a variety of diseases and conditions. The Company’s most popular product is its XinAo Xing Oleanolic Acid Capsule, an over-the-counter (“OTC”) medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. In addition to its hepatitis product, Biostar currently manufactures two broad-based OTC products, two prescription-based pharmaceuticals, one medical device and five health supplements.
Cautions about Forward Looking Statements
This press release contains forward-looking statements, including forecasts of Biostar’s future expected financial results; its prospects for the business in fiscal 2010, which fall within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. They use words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or words of similar meaning. They may also use words such as, “would,” “should,” “could” or “may.” Factors that may cause our actual results to differ materially from those described in forward-looking statements which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding the success of our investments, risks and uncertainties regarding fluctuations in earnings, our ability to sustain our previous levels of sales and profitability including on account of our ability to manage growth, intense competition, wage increases in China, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, our ability to continue our expansion in the rural areas, our ability to successfully complete and integrate potential acquisitions, withdrawal of governmental fiscal incentives, political instability and regional conflicts and legal restrictions on raising capital or acquiring companies outside China. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2009, our most Quarterly Report on Form 10-Q for the quarter ended September 30, 2010, and other recent filings. These filings are available at www.sec.gov. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in our filings with the Securities and Exchange Commission and our reports to shareholders. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Biostar disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.
For further information, contact: Bill Chen (Deyin), CFO Tel: (86)138-161-00700 Email: firstname.lastname@example.org Ted Haberfield HC International, Inc. Tel: US +1-760-755-2716 Email: email@example.com Web: http://www.hcinternational.net
SOURCE Biostar Pharmaceuticals, Inc.